Related Experiment Videos
Pain management, including intrathecal pumps.
Thomas J Smith1, Craig Swainey, Patrick J Coyne
1Division of Hematology/Oncology and Palliative Care, Massey Cancer Center of Virginia Commonwealth University, MCV Box 980230, Richmond, VA 23298-0230, USA. tsmith@hsc.vcu.edu
Current Oncology Reports
|May 27, 2004
Summary
Implantable drug delivery systems (IDDS) offer superior pain relief and reduced side effects for cancer patients compared to standard treatments. This advanced therapy improves outcomes and quality of life for those with refractory pain.
Area of Science:
- Oncology
- Pain Management
- Pharmacology
Background:
- Despite current guidelines, 14% of cancer patients experience unrelieved pain or side effects, indicating suboptimal therapy.
- Existing treatments often fail to adequately manage severe cancer-related pain and associated adverse events.
- Systemic narcotic use leads to significant toxicity and limited efficacy in refractory cases.
Purpose of the Study:
- To evaluate the efficacy and safety of implantable drug delivery systems (IDDS) for cancer pain management.
- To compare IDDS with comprehensive medical management in patients with high pain scores and refractory pain.
- To assess the impact of IDDS on pain reduction, drug toxicity, and survival in advanced cancer patients.
Main Methods:
- A large randomized trial involving 202 patients with severe pain (scores ≥7.5) despite high-dose opioid therapy.
- Comparison of IDDS with comprehensive medical management (CMM) in terms of clinical success, pain scores, and toxicity.
- Inclusion of patients with refractory pain who had previously failed a month of expert-led CMM.
Main Results:
- IDDS demonstrated significantly higher clinical success rates (84.5%) compared to CMM (70.8%, P=0.05).
- IDDS led to greater reductions in pain scores (52% vs. 39%) and drug toxicity scores (50% vs. 17%).
- Patients receiving IDDS experienced improved survival outcomes compared to the CMM group.
Conclusions:
- IDDS represent a superior treatment option for cancer patients with severe and refractory pain.
- The findings support the consideration of IDDS as a first-line or advanced therapy for optimal cancer pain management.
- IDDS effectively reduce pain and toxicity, improving the quality of life and survival in challenging patient populations.